SHANGHAI – Canbridge Life Sciences Ltd., a privately held biopharma in Beijing, has in-licensed AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate from Aveo Oncology Inc., of Cambridge, Mass. While the candidate has been tested in numerous tumor models, Canbridge will develop AV-203 in esophageal squamous cell cancer (ESCC), the most prevalent form of esophageal cancer especially in China where half of all new cases arise.
SHANGHAI – Canbridge Life Sciences Ltd., a privately held biopharma in Beijing, has in-licensed AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate from Aveo Oncology Inc., of Cambridge, Mass. While the candidate has been tested in numerous tumor models, Canbridge will develop AV-203 in esophageal squamous cell cancer (ESCC), the most prevalent form of esophageal cancer especially in China where half of all new cases arise.
SHANGHAI – While perusing the list of China's most promising biopharmaceutical companies, a surprising fact emerges: Many are not registered in China as purely domestic firms, but operate here as wholly foreign-owned enterprises under a Cayman Islands holding company. Cayman Islands is a well-known business-friendly tax haven.
SHANGHAI – Executives from Eli Lilly and Co., and multifunctional contract research organization (CRO) Wuxi Apptec came together at the Shangri-la Hotel Pudong to tout a strategic collaboration to develop a phase I, small-molecule drug that could treat cardiovascular (CV) patients with dyslipidemia. The deal, which first went public four months ago, was receiving an extra communications push, a sign of the changing times in China.
SHANGHAI – Executives from Eli Lilly and Co., and multifunctional contract research organization (CRO) Wuxi Apptec came together at the Shangri-la Hotel Pudong to tout a strategic collaboration to develop a phase I, small-molecule drug that could treat cardiovascular (CV) patients with dyslipidemia.
SHANGHAI – China's growth story is changing. For almost a decade, 15 percent growth rates year over year for the pharma sector were the norm. But in 2015, multinational corporations struggled to hit growth rates in the upper single digits and that moderate growth is expected to continue in 2016, according to BMI Research.
SHANGHAI – China's growth story is changing. For almost a decade, 15 percent growth rates year over year for the pharma sector were the norm. But in 2015, multinational corporations struggled to hit growth rates in the upper single digits and that moderate growth is expected to continue in 2016, according to BMI Research.
SHANGHAI – Impact Therapeutics Inc., a China-based biotech dedicated to the discovery and development of new drugs, has received $10 million in series B financing from five investors to support the virtual firm's lead candidate, a poly ADP-ribose polymerase (PARP) inhibitor that may have the potential to be best in class in China, if not globally.
SHANGHAI – Impact Therapeutics Inc., a China-based biotech dedicated to the discovery and development of new drugs, has received $10 million in series B financing from five investors to support the virtual firm's lead candidate, a poly ADP-ribose polymerase (PARP) inhibitor that may have the potential to be best-in-class in China, if not globally. Impact filed for an investigative new drug application (IND) for its PARP-1 inhibitor in China last month.
SHANGHAI – Sciclone Pharmaceuticals Inc., of Foster City, Calif., will pay $12.8 million to settle charges that it violated the Foreign Corrupt Practices Act (FCPA) when its international subsidiaries reportedly increased sales by making improper payments to health care professionals employed at state health institutions in China.
